Brief: Mitogen-activated protein kinases (MAPKs) are a highly conserved family of serine/threonine protein kinases involved in a variety of fundamental cellular processes such as proliferation, differentiation, motility, stress response, apoptosis, and survival.A broad range of extracellular stimuli including mitogens, cytokines, growth factors, and environmental stressors stimulate the activation of one or more MAPKK kinases (MAPKKKs) via receptor-dependent and -independent mechanisms. MAPKKKs then phosphorylate and activate a downstream MAPK kinase (MAPKK), which in turn phosphorylates and activates MAPKs. The MAPK Inhibitor Library by SAB, containing 140 compounds targeting MAPK signaling, can be used for research in MAPK signaling, and drug screening for related diseases

Brief: ThePI3K/AKT/mTOR pathwayis an intracellular signaling pathway important in regulating thecell cycle. Therefore, it is directly related to cellularquiescence,proliferation,cancer, and longevity. Phosphatidylinositol 3-kinase (PI3K), AKT, a serine/threonine protein kinase also known as protein kinase B (PKB), and mammalian target of rapamycin (mTOR) are 3 major nodes in the pathway. PI3Kactivationphosphorylatesand activatesAKT, localizing it in theplasma membrane.AKT can have a number of downstream effects such as activatingCREB,inhibitingp27,localizingFOXOin the cytoplasm,activatingPtdIns-3ps,and activatingmTORwhich can affect transcription of p70 or 4EBP1. mTOR is a component of the PI3K/AKT cell survival pathway that monitors the availability of nutrients, mitogenic signals and cellular energy and oxygen levels, a major regulator of the autophagic process, and alterations in components of the mTOR pathway have a major role in tumor progression. Therefore, mTOR is an appealing therapeutic target in many tumors. Encouraging data from preclinical studies have offered new opportunities to fully exploit the therapeutic potential of mTOR targeting in cancer. The PI3K/Akt/mTOR Compound Library by SAB, containing 190 compounds targeting PI3K/Akt/mTOR signaling, can be used for high throughput screening and high content screening for new drugs.

Brief: Epigenetics is the study of molecular processes that influence the flow of information between a constant DNA sequence and variable gene expression patterns. This includes investigation of nuclear organization, DNA methylation, histone modification and RNA transcription. Epigenetic processes can result in intergenerational (heritable) effects as well as clonal propagation of cell identity without any mutational change in DNA sequence. Epigenetics has the potential to be a key element in a paradigm change of our understanding of aging, development, cancer, heart disease, psychological disorders, and other diseases. For example, Epigenetic modifications have a considerable effect on cancer. Changes in the pattern of histone modificationsin the promoter sequences as epigenetic regulation lead to changes in chromatin structure thus may be the cause of altered gene expression by activation of oncogenes. The Epigenetics Compound Library by SAB, containing 380 compounds related to epigenetic regulation, can be used for research in epigenetics, high throughput screening and high content screening for new drugs in epigenetic modification

Brief: Protease inhibitorsaremoleculesthat inhibit the function ofproteases(enzymesthat aidthe breakdown of proteins), including proteins protease inhibitors, natural protease inhibitors, and synthetic protease inhibitors. (1). Antiprotozoal activity: protease inhibitors could be used against malaria and gastrointestinal protozoal infections; (2). Antiretrovirals: protease inhibitors were the second class of antiretroviral drugs developed widely used to treat HIV/AIDS and hepatitis C; (3). Anticancer activity: Researchers are investigating whether protease inhibitors could possibly be used to treat cancer. For example, nelfinavir and atazanavir are able to kill tumor cells in culture. Inhibitors of theproteasome, such asbortezomibare now front-line drugs for the treatment ofmultiple myeloma. Marimastat and batimastatare two of thematrix metalloproteinase inhibitorsthat can be used to treat cancer. The Protease Inhibitor Library by SAB, containing 162 small protease and proteasome inhibitors, can be used for research in Chemical Genomics and drug screening.

Brief: Traditional de novo drug discovery and development involves an HTS campaign for de novo candidate hits and requires highly specialized screening facilities and compound libraries containing several million compounds.It is a time consuming and expensive process. As the regulation for drug safety and efficacy is increasingly getting complex, the cost of developing new drugs is keeping skyrocket. Drug repositioning, also known as old drugs for new uses, is an effective strategy to find new indications for existing drugs and has recently drawn attention and has led to several blockbuster drugs because of its high efficiency and low-cost. High-content screens, new biomarkers, noninvasive imaging techniques, and advanced in bioinformatics have created new opportunities for pursuing novel indications for approved compounds. Approved drugs all have known and well-characterized bioactivities, safety and bioavailability -C properties which could dramatically accelerate drug development and optimization. Hits from this set will provide a significant head start in any drug optimization program. In addition, a growing number of compounds have been identified from this library that can functionally replace reprogramming transcription factors, enhance efficiency of iPSC generation and accelerate the reprogramming process by single use or a combination of several molecules.

Brief: Inhibitors

Brief: Inhibitors

Brief: Inhibitors

Brief: Inhibitors

Brief: Inhibitors